Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
ProQR Therapeutics, which is developing RNA therapies for genetic eye diseases, announced Wednesday that it will be restructuring and laying off 30% of its staff.
Cambridge, Massachusetts-based life sciences firm Flagship Pioneering announced that Michael Severino, who will leave AbbVie on May 31, is joining Flagship as a CEO-Partner.
Companies like Chameleon Biosciences and Code Biotherapeutics will present their latest research at the FUTURES 2022 conference hosted by CureDuchenne.
Australia’s Chimeric Therapeutics has partnered with WuXi ATU on two autologous CAR T-cell therapies for solid tumors. Switzerland-based CDR-Life closed a $76 million Series A.
This year’s AACR Annual Meeting is coming to a close, and there has been a wealth of information and data presented. One topic of discussion stood out—mutations.
Companies working on cell therapies got most of the funding in the life sciences venture capital world this week. For that and more, continue reading.
As the American Association of Cancer Research (AACR) Annual Meeting wraps up, there were some surprising and exciting research news and presentations.
Reports that myopericarditis may be a side effect of COVID-19 vaccination are downplayed by a recently published study that suggests there might not be a correlation.
As the world speculates the potential impact of the novel COVID-19 variant omicron XE and subvariant BA.2, research continues to shed light on the impact and future of the pandemic.
With Spring comes new beginnings, and companies within the biopharmaceutical industry are blossoming with fresh ventures. Here are some of them:
9 Meters Biopharma has received notice from the U.S. Patent and Trademark Office (USPTO) allowing its patent for therapeutic NM-136 to treat hyperphagia (extreme hunger) and obesity.
The FDA has sprung into action, cracking down on the illegal sales of Adderall, as well as on CBD companies making claims their products are effective treatments or cures for COVID-19.